Will the targeted drugs included in medical insurance in 2025 include mavacamten?

Mavacamten (mavacamten) is a new type of cardiac myosin inhibitor , mainly used to treat obstructive hypertrophic cardiomyopathy (HCM). The drug significantly improves patients' quality of life by regulating myocardial contraction and improving left ventricular outflow tract (LVOT) obstruction. With the extensive research and application of this drug, Mavakatai was successfully included in the national medical insurance directory on November 28, 2024. This move will undoubtedly have a positive impact on the majority of HCM patients.

After being included in the medical insurance directory, Mavakatai's financial burden will be greatly reduced. According to the current medical insurance policy, targeted drugs usually have a certain reimbursement ratio, and the specific ratio varies according to different regions and specific drugs. For Mavaceta, as a newly launched drug, the implementation of medical insurance reimbursement will allow patients to obtain more affordable prices when receiving treatment, especially when facing the drug expenditure required for long-term treatment, this policy is particularly important.

In most cases, inclusion in medical insurance means that the clinical efficacy and safety of the drug have been fully verified. Relevant research data shows that Mavaceta has obvious advantages in improving the symptoms of HCM patients. Patients can also ensure that they receive the necessary monitoring and guidance while using the drug to reduce the risk of potential side effects. In addition, the implementation of medical insurance policies has also promoted communication between hospitals and patients, making patients more clear about medication decisions and able to reasonably choose a treatment plan that suits them under the guidance of doctors.

In addition to Mavaceta,The list of targeted drugs included in medical insurance in 2025 may also include other innovative drugs targeting specific diseases. The common features of these drugs are that they are highly targeted and effective, and can improve patients' quality of life and life expectancy to a certain extent. The continuous optimization of medical insurance policies will help more innovative drugs enter the market and provide patients with more treatment options.

References:https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.124.012441